Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986454 in Healthy Participants
NCT06086886Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and autoimmune diseases comparing BMS-986454 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events (AEs) at 4 months, Number of participants with severe adverse events (SAEs) at 4 months and 4 more. Started Nov 2023; status: completed.
02
Drugs
BMS-986454
03
Conditions
rheumatoid arthritis (RA)autoimmune diseases
Beyond the preview
Go deeper on NCT06086886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086886.